Back to top
more

Insys Therapeutics, Inc. (INSY)

(Delayed Data from NSDQ)

$4.19 USD

4.19
303,567

+0.04 (0.96%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.19 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

    BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

    BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

      Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

      Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

        Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

        Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.

          CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed

          CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.

            Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact

            Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.

              Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

              Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

                Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.

                  Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines

                  Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.

                    Insulet (PODD) Shows Strength: Stock Adds 7.1% in Session

                    Insulet Corporation (PODD) moved big last session, as its shares jumped over 7% on the day.

                      Cardiovascular Systems Rides on Innovation Amid Several Woes

                      Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.

                        Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

                        Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.

                          Wright Medical Group (WMGI) Q2 Loss Narrower than Expected

                          Wright Medical Group N.V. (WMGI) posted narrower-than-expected loss on account of strong growth in the U.S.

                            Inogen (INGN) Beats Earnings and Revenue Estimates in Q2

                            Inogen (INGN) delivers better-than-expected results in Q2 with significant contributions from the Business-to-Business segment. Moreover, raised guidance buoys optimism.

                              Illumina (ILMN) Rides on New Products, Low Margin a Concern

                              Illumina (ILMN) continues to grow in high-potential genetic research market through innovation and product launches.

                                Bruker (BRKR) Q2 Earnings & Revenues Beat Estimates, View Up

                                Bruker (BRKR) delivers a better-than-expected Q2, largely driven by strength in CALID Group and BEST. Moreover, a raised guidance buoys optimism.

                                  Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance

                                  Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.

                                    Agios Pharmaceuticals (AGIO) Looks Good: Stock Adds 5.1% in Session

                                    Agios Pharmaceuticals, Inc. (AGIO) was a big mover last session, as the company saw its shares rise over 5% on the day.

                                      Cardiovascular Systems (CSII) Posts Q4 Earnings, Revenues Top

                                      Cardiovascular Systems' (CSII) lower operating expenses drove the year-over-year improvement in Q4 earnings.

                                        Is a Surprise in Store for Penumbra (PEN) in Q2 Earnings?

                                        Penumbra's (PEN) escalating costs and expenses may keep margins under pressure in the yet-to-be-reported second quarter.

                                          Genomic Health (GHDX) Posts Wider-than-Expected Loss in Q2

                                          Genomic Health (GHDX) continues to lag expectations despite strong adoption of its Oncotype DX test.

                                            Illumina (ILMN) Tops Q2 Earnings & Revenues, Raises View

                                            Illumina (ILMN) delivers an impressive Q2 on strong uptake of sequencing consumables and microarrays and continued adoption of NovaSeq platform. A raised guidance buoys optimism.

                                              ResMed (RMD) Q4 Earnings Top, 2020 Strategic Goals on Track

                                              ResMed's Q4 results (RMD) register strong sales in sleep devices, respiratory care devices, mask systems and software solutions.

                                                DaVita (DVA) Beats Earnings and Revenue Estimates in Q2

                                                DaVita's (DVA) stable performance across its businesses was the key highlight of the second quarter.

                                                  VWR Corp (VWR) Beats Earnings & Revenue Estimates in Q2

                                                  VWR Corp (VWR) reported an impressive Q2 and is presently awaiting a merger with Avantor.